The life sciences sector is booming across Arizona, and Phoenix has ranked in the top ten for year-over-year growth in life sciences degrees and certificates in the market. This indicates that Arizona is not only a hub for life sciences R&D but also a region assisting in the life cycle of talent development for this booming sector. Caris Life Sciences, a leading, patient-centric, next-generation AI TechBio company, is proud to contribute to this ongoing advancement here in Phoenix.
Since its 2008 founding, Caris has invested more than $450 million in Arizona, building five major facilities, approaching 270,000 in square feet total and creating jobs for more than 950 Arizonans. In June 2025, we’re grateful to have gone public with a successful $494-million IPO.
Our investment in Arizona has enabled local talent to develop and carry out molecular profiling with powerful AI-driven assays (tests) as we focus on helping thousands of oncologists across the country personalize cancer treatment. In our labs we’ve performed more than 6.5 million molecular tests across more than 849,000 patient cases.
Arizona is a hub for Caris’ development of next-generation AI-powered healthcare solutions, supported by the state’s policies that encourage innovation.
The 2022 passage of Arizona’s HB 2144, requiring health insurers to cover some biomarker testing, marked a pivotal step in expanding access to precision medicine. Arizona’s reputation as a center for advanced science was underscored in November 2024 when Caris’ MI Cancer Seek assay earned FDA approval as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
Growth and innovation attract top talent and reinforce Arizona’s standing as a destination for life sciences investment. The future of life sciences in Arizona has never looked brighter.
David Spetzler is president of Caris Life Sciences.
